EMPLOYMENT AGREEMENTEmployment Agreement • February 1st, 2007 • Sucampo Pharmaceuticals, Inc. • Pharmaceutical preparations
THIS EMPLOYMENT AGREEMENT (the “Agreement”), dated as of January 2, 2007 (the “Effective Date”), is hereby entered into in the State of Maryland by and between SUCAMPO PHARMACEUTICALS, INC., a Delaware corporation (the “Company”), and Ronald W. Kaiser (“Executive”).
Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions. COLLABORATION AND LICENSE AGREEMENTCollaboration and License Agreement • February 1st, 2007 • Sucampo Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
THIS COLLABORATION AND LICENSE AGREEMENT (the “Agreement”) is made as of October 29, 2004, by and between Sucampo Pharmaceuticals, Inc., a corporation organized under the laws of Delaware, having its principal place of business at 4733 Bethesda Avenue, Suite 450, Bethesda, Maryland 20814 USA (“SPI”), and Takeda Pharmaceutical Company Limited, a corporation organized under the laws of Japan, having its principal place of business at 1-1 Doshomachi 4-chome, Chuo-ku, Osaka 540-8645, Japan (“Takeda”). SPI and Takeda are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
SUPPLY AND PURCHASE AGREEMENTSupply and Purchase Agreement • February 1st, 2007 • Sucampo Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
THIS SUPPLY AND PURCHASE AGREEMENT is made as of January 25, 2006, by and among Sucampo Pharmaceuticals, Inc., a Delaware corporation having its principal place of business at 4733 Bethesda Avenue, Suite 450, Bethesda, Maryland 20814 USA (“SPI”), Takeda Pharmaceutical Company Limited, a corporation organized under the laws of Japan having its principal place of business at 1-1, Doshomachi 4-chome, Chuo-ku, Osaka 540-8645, JAPAN (“Takeda”) and R-Tech Ueno, Ltd., a corporation organized under the laws of Japan having its principal place of business at 10F, Yamato Life Insurance Bldg., 1-1-7 Uchisaiwaicho, Chiyoda-ku, Tokyo 100-0011, JAPAN (“RTU”) (this “Agreement”). SPI, Takeda and RTU are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
October 30, 2006 Sachiko Kuno, Ph.D. 24687 Yacht Club Road St. Michael, MD 21663 Re: Amendment to Employment Agreement Dear Dr. Kuno:Employment Agreement • February 1st, 2007 • Sucampo Pharmaceuticals, Inc. • Pharmaceutical preparations
This letter will reflect the agreement between you and Sucampo Pharmaceuticals, Inc. (the “Company”) upon the terms of an amendment to the Employment Agreement between you and the Company dated June 16, 2006. At its September 7, 2006 meeting, the Company’s Board of Directors adopted a resolution providing that you will remain as President of the Company and, effective September 30, 2006, you would become Chairman of the Board of Directors of the Company. Consistent with the requirements for modification set forth in Section 6.3 of the Employment Agreement, this letter will document the mutual agreement between you and the Company to amend Section 1.1 of your Employment Agreement to provide that, effective September 30, 2006, you will be employed by the Company as its President and as the Chairman of its Board of Directors, but will cease to serve as the Company’s Chief Executive Officer. These are the only changes to the terms of the Employment Agreement to be made at this time.
October 30, 2006 Ryuji Ueno, M.D., Ph.D. 24687 Yacht Club Road St. Michael, MD 21663 Re: Amendment to Employment Agreement Dear Dr. Ueno:Employment Agreement • February 1st, 2007 • Sucampo Pharmaceuticals, Inc. • Pharmaceutical preparations
This letter will reflect the agreement between you and Sucampo Pharmaceuticals, Inc. (the “Company”) upon the terms of an amendment to the Employment Agreement between you and the Company dated June 16, 2006. At its September 7, 2006 meeting, the Company’s Board of Directors adopted a resolution providing that you will remain as Chief Scientific Officer of the Company and, effective September 30, 2006, you would become Chief Executive Officer of the Company. Consistent with the requirements for modification set forth in Section 6.3 of the Employment Agreement, this letter will document the mutual agreement between you and the Company to amend Section 1.1 of your Employment Agreement to provide that, effective September 30, 2006, you will be employed by the Company as its Chief Executive Officer and as its Chief Scientific Officer, but will cease to serve as the Company’s Chief Operating Officer. These are the only changes to the terms of the Employment Agreement to be made at this time
